File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: High-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients

TitleHigh-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients
Authors
KeywordsLiver transplant
Ablation
Bridging therapy
Cirrhosis
Hepatocellular carcinoma
New technology
High-intensity focused ultrasound
Issue Date2013
Citation
World Journal of Gastroenterology, 2013, v. 19, n. 20, p. 3083-3089 How to Cite?
AbstractAIM: To analyze whether high-intensity focused ultrasound (HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma (HCC). METHODS: From January 2007 to December 2010, 49 consecutive HCC patients were listed for liver transplantation (UCSF criteria). The median waiting time for transplantation was 9.5 mo. Twenty-nine patients received transarterial chemoembolization (TACE) as a bringing therapy and 16 patients received no treatment before transplantation. Five patients received HIFU ablation as a bridging therapy. Another five patients with the same tumor staging (within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison. Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores, tumor size and number, and cause of cirrhosis. RESULTS: The HIFU group and TACE group showed no difference in terms of tumor size and tumor number. One patient in the HIFU group and no patient in the TACE group had gross ascites. The median hospital stay was 1 d (range, 1-21 d) in the TACE group and two days (range, 1-9 d) in the HIFU group (P < 0.000). No HIFU-related complication occurred. In the HIFU group, nine patients (90%) had complete response and one patient (10%) had partial response to the treatment. In the TACE group, only one patient (3%) had response to the treatment while 14 patients (48%) had stable disease and 14 patients (48%) had progressive disease (P = 0.00). Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list (P = 0.559). CONCLUSION: HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis. It may reduce the drop-out rate of liver transplant candidate. © 2013 Baishideng. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/221339
ISSN
2015 Impact Factor: 2.787
2015 SCImago Journal Rankings: 1.076
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, TT-
dc.contributor.authorFan, ST-
dc.contributor.authorChan, SC-
dc.contributor.authorChok, KSH-
dc.contributor.authorChu, FSK-
dc.contributor.authorJenkins, CR-
dc.contributor.authorLo, RCL-
dc.contributor.authorFung, JYY-
dc.contributor.authorChan, ACY-
dc.contributor.authorSharr, WW-
dc.contributor.authorTsang, SHY-
dc.contributor.authorDai, WC-
dc.contributor.authorPoon, RTP-
dc.contributor.authorLo, CM-
dc.date.accessioned2015-11-18T06:09:03Z-
dc.date.available2015-11-18T06:09:03Z-
dc.date.issued2013-
dc.identifier.citationWorld Journal of Gastroenterology, 2013, v. 19, n. 20, p. 3083-3089-
dc.identifier.issn1007-9327-
dc.identifier.urihttp://hdl.handle.net/10722/221339-
dc.description.abstractAIM: To analyze whether high-intensity focused ultrasound (HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma (HCC). METHODS: From January 2007 to December 2010, 49 consecutive HCC patients were listed for liver transplantation (UCSF criteria). The median waiting time for transplantation was 9.5 mo. Twenty-nine patients received transarterial chemoembolization (TACE) as a bringing therapy and 16 patients received no treatment before transplantation. Five patients received HIFU ablation as a bridging therapy. Another five patients with the same tumor staging (within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison. Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores, tumor size and number, and cause of cirrhosis. RESULTS: The HIFU group and TACE group showed no difference in terms of tumor size and tumor number. One patient in the HIFU group and no patient in the TACE group had gross ascites. The median hospital stay was 1 d (range, 1-21 d) in the TACE group and two days (range, 1-9 d) in the HIFU group (P < 0.000). No HIFU-related complication occurred. In the HIFU group, nine patients (90%) had complete response and one patient (10%) had partial response to the treatment. In the TACE group, only one patient (3%) had response to the treatment while 14 patients (48%) had stable disease and 14 patients (48%) had progressive disease (P = 0.00). Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list (P = 0.559). CONCLUSION: HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis. It may reduce the drop-out rate of liver transplant candidate. © 2013 Baishideng. All rights reserved.-
dc.languageeng-
dc.relation.ispartofWorld Journal of Gastroenterology-
dc.subjectLiver transplant-
dc.subjectAblation-
dc.subjectBridging therapy-
dc.subjectCirrhosis-
dc.subjectHepatocellular carcinoma-
dc.subjectNew technology-
dc.subjectHigh-intensity focused ultrasound-
dc.titleHigh-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.3748/wjg.v19.i20.3083-
dc.identifier.pmid23716988-
dc.identifier.pmcidPMC3662948-
dc.identifier.scopuseid_2-s2.0-84878238001-
dc.identifier.hkuros220052-
dc.identifier.volume19-
dc.identifier.issue20-
dc.identifier.spage3083-
dc.identifier.epage3089-
dc.identifier.eissn2219-2840-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats